Stratolaunch successfully completed its hypersonic test flight earlier this year. Image courtesy of Draper

With a recent air-launched test vehicle flight that came close to hypersonic speed, research company Draper has accelerated the potential for its flight technology.

Draper, a Cambridge, Massachusetts-based nonprofit, provided the crucial guidance, navigation, and control flight software for the flight. That guidance system was built on the same Draper technology that NASA has used in its Apollo mission, the international space station and space shuttle programs.

“In a broad sense, Draper has been working hypersonic since Apollo,” Rick Loffi, space systems program manager and lead executive for Draper’s Houston campus, tells InnovationMap.

The navigation software controlled the first powered test flight of an air-launched vehicle that approached the hypersonic threshold of Mach 5, or 3,800 miles per hour, or five times the speed of sound.

Stratolaunch successfully completed the flight of its TA-1 Talon test vehicle in the Mojave Desert in March. The California-based company designs and launches aerospace vehicles and technologies, providing access to a reusable hypersonic testing platform, according to its website. The historic test flight landed in the Pacific Ocean, and achieved successful ignition, acceleration and sustained altitude climb.

“The Draper software is really what’s stabilizing the vehicle during flight…and controlling it as it gets up into altitude and speed,” Brandon Jalbert, space systems program manager for Draper and team lead for Stratolaunch, says “so it’s not doing loop-de-loops, or getting unstable…blowing up in the atmosphere.”

Draper uses model-based design and algorithms in its software, and for the boost phase of the Talon test, Draper developed a novel algorithm, which built upon its previous work for NASA, Jalbert says.

Aerospace manufacturing companies like Boom and Hermeus stand poised to pick up where the Concorde left off, and are racing to implement and execute on accessible hypersonic and supersonic commercial technology.

The Concorde aircraft made supersonic, four-hour transoceanic flights a reality, but only for the very wealthy, and shut down in 2003.

Draper is not involved in any of those ventures to bring accessible supersonic flight back to the skies. Its primary focus with hypersonic will remain with deterrence and testing platforms, Jalbert says.

But the company’s technology “has applications everywhere from military to commercial activity,“ he says.

“Our focus is to solve complex challenges of national importance,” he says, “whether that’s…helping our commercial partners, or working on civil or military applications. That’s where we see ourselves being of value to the industry.”

With the harsh conditions involved in hypersonic flight, advancing the technology has its challenges.

“You’ve got to have proper hardware and electronics and sensors that can operate within those conditions,” Jalbert says.

Draper originated in 1932 when engineer Charles Stark Draper founded what eventually became the Instrumentation Lab at MIT.

His work on inertial navigation theory paved the way for the use of the autopilot in today’s commercial jets. The lab was divested by MIT in the 1970s, and became a nonprofit. Draper has long been a government contractor and has worked on many military projects, dating to WWII.

Draper in 2023 secured the $2.2 billion renewal of a long-standing contract with the U.S. Navy to provide the guidance system for the submarine-launched Trident II D-5 missile.

The U.S. government has shown a growing interest in the development of hypersonic weapons systems, as Russia and China have developed advanced capabilities.

The Pentagon’s budget request for hypersonic research for fiscal year 2025 was $6.9 billion, up from $4.7 billion for 2023, according to a recent U.S. Naval Institute report.

“There’s a big shift, in deterrence, as well as offensive, on hypersonic,” Jalbert says.

However, the Defense Department has not yet acquired hypersonic weapons, according to the report, but is developing prototypes and testing.

Draper has a long, celebrated history with NASA, and its Houston office is housed at Johnson Space Center. Draper's presence in Houston dates back to the 1960s, Loffi says.

From the Apollo missions to the space station and now the Artemis program, which aims to land the first person of color and the first woman on the moon by 2026 on its Orion spacecraft, Draper has partnered with NASA every step of the way, providing its navigation system for space flight.

“Right now, our biggest customer within NASA is the Orion program,” Loffi says, with approximately 15 of the 20-person Houston office working on the project, in collaboration with the company’s Cambridge colleagues.

Draper's Houston office is working on NASA's Orion program. Photo via NASA

The company is also working with NASA on lunar landing technology and sub-orbital experiments, as well as the propulsion element and Gateway space station for Artemis.

Amazon founder Jeff Bezos’s aerospace manufacturing company Blue Origin is also partnering with Draper to develop the Artemis human landing system.

Neither Loffi nor Jalbert aspired to go into outer space themselves, but rather to provide solutions to make that possible. Human spaceflight has been a lifelong passion for Loffi.

While he had lots of job opportunities after graduating from Purdue University with a degree in electrical engineering, Loffi chose NASA.

“I wasn’t that person who grew up dreaming of becoming an astronaut,” Loffi says. “I was old enough to see the Apollo 11 moon landing, and it did inspire me.”

His work at NASA began after the space shuttle Challenger explosion, in 1986. He was part of the agency’s effort to return to space flight, and worked on space station development, before joining Draper in 2011.

Jalbert, a graduate of Northeastern University, says his early work at Draper “lit the fires for my interest in space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.